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Post Hoc Analysis of the Phase II/III APRIL-SLE Study
Association Between Response to Atacicept and Serum Biomarkers Including
BLyS and APRIL
Caroline Gordon,1 David Wofsy,2 Stephen Wax,3 Yong Li,3
Claudia Pena Rossi,4 and David Isenberg5
Objective. To assess the relationship between
treatment response, baseline biomarker levels, and
atacicept exposure in patients with systemic lupus ery-
thematosus (SLE) in the phase II/III APRIL-SLE study.
Methods. We performed a post hoc analysis of
patients who received placebo, atacicept 75 mg, or atacicept
150 mg in a randomized, controlled, 52-week trial. Serum
levels of BlyS and APRIL were measured at baseline, and
serum levels of Ig and the numbers of naive B cells and
plasma cells were measured at baseline and during treat-
ment. Atacicept exposure was determined by assessment of
the serum trough concentrations throughout the 52-week
trial period. Associations between these parameters, treat-
ment response (reduction inBritish Isles LupusAssessment
GroupA or B flare), and infection rates were explored.
Results. Recurrent high baseline levels of both
BLyS (‡1.6 ng/ml) and APRIL (‡2.2 ng/ml) correlated
with a greater treatment response (flare rate 75.7% with
placebo, and 50.0% and 32.0% with atacicept 75 mg and
atacicept 150 mg, respectively) compared with lower base-
line levels of both. Increased atacicept exposure correlated
with reduced flare rates (60.5% with placebo; 63.4%, 61.0%,
48.8%, and 29.3% in the 4 quartiles, from lowest to highest
atacicept exposure). Greater pharmacodynamic responses
(reduced Ig levels and naive B cell and plasma cell num-
bers) were associated with greater reductions in the flare
rate. Infection rates were similar regardless of biomarker
levels at baseline or at the time of atacicept exposure.
Conclusion. These post hoc analyses demonstrate a
dose-response relationship between atacicept concentra-
tions, reduced Ig levels, and reduced flare rates and sug-
gest that baseline biomarkers such as elevated serum
levels of BLyS and APRILmay help to identify the patients
who aremost likely to benefit from atacicept treatment.
Systemic lupus erythematosus (SLE) is a chronic,
potentially fatal autoimmune disease characterized by
unpredictable exacerbations and remissions, with pro-
tean clinical manifestations (1–4). The severity of dis-
ease ranges from mild to life-threatening, and many
SLE patients consider their general quality of life to be
poor (5,6). Patients with SLE are chronically exposed to
drugs that have significant side effects, such as cor-
ticosteroids and immunosuppressive agents (7). There
is a high unmet need for novel therapies with improved
risk/benefit ratios that specifically target manifestations
of SLE and improve patients’ quality of life. New therapies
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should reduce the need for immunosuppressive agents
and corticosteroids, control end-organ damage, reduce
mortality, and limit side effects (8).
B cell abnormalities contribute to the clinical mani-
festations of SLE; therefore, diverse strategies have been
proposed to target B cells in this disease (9,10). Patients
with SLE who do not respond to treatment with standard
immunosuppressive agents are increasingly considered for
targeted biologic treatments directed at B cell–activating
factors, B cells and T cells, and cytokines. Blockade of B
cells is of specific importance, because lupus auto-
antibodies play a key role in the pathophysiology of the
disease (11). Inhibition of the B cell–stimulating factor
BLyS (also known as BAFF) (12) with the monoclonal
antibody belimumabwas shown to be effective for the treat-
ment of SLE and to have an acceptable safety profile (13).
Atacicept (previously referred to as TACI-Ig) is a
recombinant fusion protein comprised of the extracellular
domain of the TACI receptor joined to a human IgG1 Fc
domain (14). Like belimumab, atacicept inhibits BLyS.
Atacicept also targets APRIL (12,14), another B cell–
stimulating factor that plays a critical role in SLE path-
ogenesis (15) and promotes the survival of long-lived
plasma cells and plasmablasts (16,17), which are be-
lieved to contribute to the production of autoantibodies
observed in SLE (18). Both BLyS and APRIL levels are
elevated in patients with SLE (15,19,20), which suggests
that blocking the activities of both BLyS and APRIL by
atacicept may result in an effective approach to treatment.
In contrast to inhibition of BLyS alone, simultaneous inhi-
bition of APRIL has the potential added benefit of target-
ing long-lived plasma cells, thus reducing autoantibody
production.
In a phase II/III randomized, double-blind, multi-
center, placebo-controlled trial (APRIL-SLE; n5 461)
(ClinicalTrials.gov identifier: NCT00624338), there was no
difference in flare rates between atacicept 75 mg and pla-
cebo (odds ratio [OR] 1.15, P 5 0.543). Due to 2 fatal
infections among patients receiving atacicept 150 mg (1 of
which was caused by acute respiratory failure secondary to
possible leptospirosis, which is an extremely rare cause of
death in SLE), this treatment arm was terminated before
it was fully enrolled. However, analysis of patients treated
at the higher atacicept dose suggested efficacy in the pre-
vention of flare (P 5 0.002) and increased time to first
flare (P5 0.009) when compared with placebo (21).
We performed a post hoc analysis to examine the
relationships between atacicept efficacy and safety out-
comes and patient biomarkers (BLyS and APRIL levels,
Ig levels, and naive B cell and plasma cell numbers) as
well as drug exposure levels in the potential completer
population of the APRIL-SLE study, which includes all
patients who were randomized more than 52 weeks
prior to termination of the atacicept 150-mg arm and
were therefore not affected by this discontinuation.
PATIENTS AND METHODS
Trial design. Details of the trial design and methods
have been described previously (21). The trial was conducted in
accordance with the Declaration of Helsinki. The trial protocol
and all substantial amendments were approved by the relevant
institutional review boards or independent ethics committees,
and all patients provided written informed consent. Briefly,
exclusion criteria included active moderate-to-severe glomerulo-
nephritis or severe central nervous system lupus. Adult patients
with SLE who were antinuclear autoantibody positive (HEp-2
dilution$1:80 or anti–double-stranded DNA [anti-dsDNA] anti-
body level $30 IU/ml) and had active disease ($1 British Isles
Lupus Assessment Group [BILAG] score of A and/or B) (22) at
screening were enrolled and treated initially with a tapering
course of corticosteroids.
Patients achieving a BILAG score of C or D in all sys-
tems at week 10, without any new A or B scores by week 12
(n5 461) while receiving prednisone 7.5 mg/day in weeks 11
and 12, were randomized to receive subcutaneous injections of
atacicept 75 mg or 150 mg or matching placebo (1:1:1 ratio).
Treatment was administered twice weekly for 4 weeks and
then once weekly for the remaining 48 weeks.
The primary outcome measure was the proportion of
patients with at least 1 adjudicated BILAGA/B flare, as defined
by the BILAG index, during the 52-week trial period (termed
“flare rate”) (21). Secondary end points included time to first
flare and safety. Post hoc analyses were performed to assess the
relationship between treatment response (reduction in the num-
ber of patients with a new flare) and biomarker levels (pre-dose
BLyS at baseline, pre-dose APRIL at baseline, changes in IgG,
IgM, naive B cell numbers, and plasma cell numbers from base-
line to week 52 [or last value during treatment in case of missing
week 52 data]), and atacicept exposure (average serum trough
concentration). The association between infection rate and bio-
markers or atacicept exposure was also analyzed.
Statistical analysis. All patients included in these
analyses were those who had been randomized at least 52
weeks prior to the termination of the 150-mg treatment arm.
This population is defined as the potential completer popula-
tion on the basis that, barring any need for treatment discon-
tinuation, these patients would have completed the planned
52-week treatment. By focusing on this patient population
rather than the intent-to-treat (ITT) population, any poten-
tially confounding influence due to early termination of the
150-mg treatment arm was avoided, and comparability in
exposure between treatment groups was ensured.
For the BLyS and APRIL analysis, baseline (pre-dose)
serum levels of BLyS and APRIL were obtained, and subgroups
based on BLyS and APRIL levels were investigated to identify
whether a subset of patients with an enhanced response to
atacicept existed. For other biomarker analyses and atacicept
exposure analyses, patient data were divided into quartiles.
The primary efficacy end point was the percent of
patients with a new adjudicated BILAG A/B flare during
the 52-week treatment period (flare rate), and premature
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discontinuation of study drug was imputed as new flare.
Time to first new flare was estimated with Kaplan-Meier
curves, and treatment discontinuation was handled by
censoring.
RESULTS
Baseline characteristics. The demographic and
baseline data were comparable across all treatment groups
Figure 1. Atacicept treatment is associated with disease flare reduction in patients with high baseline serum levels of BLyS and APRIL (poten-
tial completer population). A, Flare rate (proportion of atacicept- and placebo-treated patients with a new flare) according to baseline levels of
BLyS and APRIL. Lines represent the 90% confidence limit. B, Mean IgG reduction from baseline to week 52 in atacicept- and placebo-treated
patients, according to baseline levels of BLyS and APRIL. The cutoff for high versus low BLyS levels was defined as $1.6 ng/ml. The cutoff for
high versus low APRIL levels was defined as $2.2 ng/ml. Values are the mean6 SD.
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in the ITT population. Among the 461 patients in the ITT
population, 246 were included in the potential completer
population: 81 in the placebo group, 84 in the atacicept
75 mg group, and 81 in the atacicept 150 mg group (21).
The baseline distributions of pre-dose BLyS and
APRIL levels were similar between treatment groups.
Median baseline BLyS levels were 1.9 ng/ml in all treat-
ment groups. A total of 40% of samples were below the
lower limit of quantification (LLQ) for the BLyS assay
(1.56 ng/ml) and were imputed to be the LLQ value.
Median baseline APRIL levels were 2.4 ng/ml, 2.3 ng/ml,
and 2.2 ng/ml in the placebo, atacicept 75 mg, and atacicept
150 mg groups, respectively. No samples were below the
LLQ of 0.3125 ng/ml for the APRIL assay. The baseline
serum levels of Ig as well as the naive B cell and plasma cell
counts were comparable between treatment groups.
Treatment response. Identification of patient sub-
groups with different degrees of treatment response according
to baseline BLyS and APRIL levels. A marked difference
in response to atacicept 150 mg (reduced rate of flares)
was observed in patients with baseline BLyS levels of
$1.6 ng/ml compared with those with baseline levels of
,1.6 ng/ml (see Supplementary Table 1, available on the
Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.39809/abstract). In the group
with a BLyS level of$1.6 ng/ml, there was a trend toward
a greater treatment response in patients with higher lev-
els of APRIL (see Supplementary Tables 2 and 3, avail-
able on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.39809/abstract).
A subset of patients with baseline BLyS levels of$1.6 ng/ml
and baseline APRIL levels of $2.2 ng/ml was identified as
having a significant treatment response compared with
placebo. A subset of patients with baseline BLyS levels of
$1.6 ng/ml and baseline APRIL levels of ,2.2 ng/ml was
identified as having a moderate treatment response com-
pared with placebo. In the remaining population of patients
with BLyS levels of ,1.6 ng/ml, no difference in treatment
response based on APRIL levels was detected (data not
shown). Therefore, 3 distinct BLyS/APRIL subgroups
could be defined based on the response to atacicept: sub-
group 1 (high BLyS/high APRIL), subgroup 2 (high BLyS/
lowAPRIL), and subgroup 3 (lowBLyS).
Relationship between treatment response and
baseline BLyS and APRIL levels. In patients receiving
placebo, flare rates were 75.7%, 62.5%, and 39.3% in
BLyS/APRIL subgroups 1, 2, and 3, respectively. In sub-
group 1, atacicept treatment at both doses was associ-
ated with a reduced flare rate compared with placebo;
however, this effect was most pronounced with the
higher dose of atacicept (75.7% in the placebo group,
50.0% in the atacicept 75 mg group, and 32.0% in the
atacicept 150 mg group). In subgroup 2, the flare rate
was reduced compared with placebo only at the highest
atacicept dose (62.5% in the placebo group, 84.2% in
the atacicept 75 mg group, and 48.0% in the atacicept
150 mg group). No reduction in the flare rate was
observed with atacicept compared with placebo in sub-
group 3 (39.3% in the placebo group, 51.7% in the
atacicept 75 mg group, and 48.4% in the atacicept
150 mg group) (Figure 1A).
Examination of IgG levels in the BLyS/APRIL
subgroups revealed a dose-dependent correlation
between the mean IgG change from baseline to week 52
and atacicept treatment that was comparable in all 3
subgroups (Figure 1B). These results suggest that differ-
ences in response between subgroups were not solely
attributable to the reductions in IgG levels.
Atacicept treatment appeared to delay the time
to new flare in subgroup 1 (Kaplan-Meier 25th percen-
tiles 85 days with placebo, 275 days with atacicept
75 mg, and at least 365 days with atacicept 150 mg [as
the number of patients experiencing a new flare was not
reached in the 25th percentile within 52 weeks]), but not
in subgroups 2 and 3 (see Supplementary Table 4, avail-
able on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.39809/abstract).
Relationship between treatment response and
IgG, IgM, IgA, naive B cells, and plasma cells. To ana-
lyze the relationship between treatment response and a
reduction at 52 weeks relative to baseline in IgG, IgM,
and IgA levels, naive B cells, and plasma cells, data on
atacicept-treated patients were divided into quartiles. In
addition to reductions from baseline to 52 weeks, data
on the lowest IgG values recorded during the treatment
period were also divided into quartiles and analyzed.
In terms of IgG levels, atacicept treatment was
associated with reduced flare rates compared with pla-
cebo in patients with the highest reduction in IgG levels
relative to baseline (60.5% in the placebo group, 38.5%
and 37.5% in the first and second quartiles, respectively,
compared with 60.0% and 62.5% in the third and fourth
quartiles, respectively) (Table 1), and in those who
achieved the lowest IgG levels during the study period
(43.6% and 34.1% in the first and second quartiles,
respectively, compared with 61.1% and 60.0% in the
third and fourth quartiles, respectively) (data not
shown). Flare rates were also reduced with atacicept
compared with placebo in patients with the greatest
reductions from baseline in IgM levels (43.6%) and IgA
levels (35.9%) (results not shown), as well as those with
the greatest reductions in naive B cells and plasma cells
(42.1% and 47.4%, respectively) (Table 1).
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Relationship between treatment response and
atacicept exposure. For the analysis of treatment response
according to atacicept exposure, atacicept-treated patients
were categorized into quartiles according to the average
atacicept serum trough concentration over time. Flare
rates were reduced in patients with higher levels of
atacicept exposure (48.8% and 29.3% in the third and
fourth quartiles, respectively) relative to those with lower
levels of exposure (63.4% and 61.0% in the first and sec-
ond quartiles, respectively) or those who received placebo
(60.5%) (Table 2).
Safety. Relationship between infection rate and
biomarker levels. There was no notable difference in the
overall infection rate or the rate of serious or severe
infection with atacicept compared with placebo in any
of the 3 BLyS/APRIL subgroups (Table 3). Despite
some small numerical differences, there was no correla-
tion between the overall infection rate and reduced
levels of IgG, IgM, or IgA or reduced naive B cell or
plasma cell numbers (Table 4). Although higher rates of
serious or severe infections were observed in patients
with the greatest reductions in the IgM level compared
with those with the lowest reduction (12.8% [n5 5] ver-
sus 0.0% [n5 0] for the first quartile compared with the
fourth quartile), these data reflect small numbers of
patients. No other trends toward an increased number
of serious or severe infections were observed in any
other biomarker quartiles.
Table 1. New disease flares in placebo- and atacicept-treated patients in the potential completer pop-
ulation, according to IgG, naive B cell, and plasma cell changes from baseline to week 52*
No. of
patients
New flare during
treatment
Placebo 80† 49 (60.5) [0.508–0.696]
Atacicept
Change in IgG, gm/liter
First quartile (215.4 to 26.3) 39 15 (38.5) [0.254–0.529]
Second quartile (26.2 to 24.0) 40 15 (37.5) [0.247–0.517]
Third quartile (23.9 to 22.9) 40 24 (60.0) [0.458–0.731]
Fourth quartile (22.8 to 2.0) 40 25 (62.5) [0.483–0.753]
Change in naive B cells/ml
First quartile (2725.0 to 2125.0) 19 8 (42.1) [0.230–0.632]
Second quartile (2124.0 to 244.0) 20 7 (35.0) [0.177–0.558]
Third quartile (241.0 to 212.0) 18 11 (61.1) [0.392–0.801]
Fourth quartile (211.0 to 39.0) 21 12 (57.1) [0.372–0.755]
Change in plasma cells/ml
First quartile (2107.0 to 213.0) 19 9 (47.4) [0.274–0.680]
Second quartile (212.0 to 23.0) 16 6 (37.5) [0.178–0.609]
Third quartile (22.0 to 21.0) 16 9 (56.3) [0.333–0.773]
Fourth quartile (0.0 to 136.0) 27 14 (51.9) [0.347–0.687]
* The potential completer population includes all patients who were randomized more than 52 weeks
prior to termination of the atacicept 150-mg arm. Values are the number (%) [90% confidence limit].
† The number of patients in the placebo-treated group in the IgG analysis was 81, and the number of
patients in the placebo-treated group in both the naive B cell and plasma cell analyses was 41.
Table 2. Rate of new disease flares in the placebo-treated and atacicept-treated patients in the poten-
tial completer population, according to atacicept exposure*
No. of
patients
New flare
during treatment
Placebo 81 49 (60.5) [0.508–0.696]
Atacicept
Average serum trough
concentration, ng/ml
First quartile (0.0 to 2,782.0) 41 26 (63.4) [0.494–0.759]
Second quartile (2,823.7 to 3,892.0) 41 25 (61.0) [0.469–0.738]
Third quartile (3,894.3 to 4,946.9) 41 20 (48.8) [0.351–0.626]
Fourth quartile (4,956.9 to 7,788.1) 41 12 (29.3) [0.178–0.431]
* The potential completer population includes all patients who were randomized more than 52 weeks
prior to termination of the atacicept 150-mg arm. Values are the number (%) [90% confidence limit].
126 GORDON ET AL
Neither of the 2 patients who died while receiving
atacicept had an IgG level of ,14.6 gm/liter (normal 7.0–
16.0), and their lowest post-baseline values, representing a
19.0% and a 40.0% decrease from baseline, respectively,
were still within normal levels (data not shown). Their IgM
levels remained .0.34 gm/liter (normal 0.4–2.3), and their
Table 3. Rate of infection in atacicept- and placebo-treated patients in the potential completer population, according to
baseline levels of BLyS and APRIL*
Placebo Atacicept 75 mg Atacicept 150 mg
Subgroup 1, high BlyS/high APRIL
No. of patients 37 34 25
Any infection 21 (56.8) [0.420–0.707] 19 (55.9) [0.405–0.705] 13 (52.0) [0.341–0.695]
Serious/severe infection 3 (8.1) [0.022–0.196] 0 (0.0) 1 (4.0) [0.002–0.176]
Subgroup 2, high BlyS/low APRIL
No. of patients 16 19 25
Any infection 10 (62.5) [0.391–0.822] 13 (68.4) [0.470–0.853] 17 (68.0) [0.496–0.830]
Serious/severe infection 0 (0.0) 1 (5.3) [0.003–0.226] 4 (16.0) [0.057–0.330]
Subgroup 3, low BlyS
No. of patients 28 29 31
Any infection 14 (50.0) [0.333–0.667] 16 (55.2) [0.384–0.711] 18 (58.1) [0.418–0.731]
Serious/severe infection 0 (0.0) 3 (10.3) [0.029–0.246] 3 (9.7) [0.027–0.232]
* The potential completer population includes all patients who were randomized more than 52 weeks prior to termination
of the atacicept 150-mg arm. The cutoff for high versus low BLyS levels was defined as $1.6 ng/ml. The cutoff for high ver-
sus low APRIL levels was defined as $2.2 ng/ml. Values are the number (%) of patients [90% confidence limit].
Table 4. Rate of infection in atacicept- and placebo-treated patients in the potential completer population, according to
change in IgG, IgA, IgM, naive B cell, and plasma cell levels from baseline to week 52, and atacicept exposure*
No. of
patients
Any infection
during treatment
Serious/severe infection
during treatment
Placebo 81 45 (55.6) [0.458–0.650] 3 (3.7) [0.010–0.093]
Atacicept
Change in IgG, gm/liter
First quartile (215.4 to 26.3) 39 23 (59.0) [0.446–0.723] 4 (10.3) [0.036–0.220]
Second quartile (26.2 to 24.0) 40 27 (67.5) [0.534–0.796] 3 (7.5) [0.021–0.183]
Third quartile (23.9 to 22.9) 40 24 (60.0) [0.458–0.731] 2 (5.0) [0.009–0.149]
Fourth quartile (22.8 to 2.0) 40 22 (55.0) [0.409–0.685] 3 (7.5) [0.021–0.183]
Change in IgM, gm/liter
First quartile (24.4 to 21.0) 39 24 (61.5) [0.471–0.746] 5 (12.8) [0.052–0.251]
Second quartile (20.9 to 20.7) 39 25 (64.1) [0.497–0.768] 5 (12.8) [0.052–0.251]
Third quartile (20.6 to 20.4) 39 22 (56.4) [0.421–0.700] 2 (5.1) [0.009–0.153]
Fourth quartile (20.3 to 0.7) 42 25 (59.5) [0.457–0.723] 0 (0)
Change in IgA, gm/liter
First quartile (25.0 to 21.9) 39 22 (56.4) [0.421–0.700] 4 (10.3) [0.036–0.220]
Second quartile (21.8 to 21.4) 40 26 (65.0) [0.508–0.774] 3 (7.5) [0.021–0.183]
Third quartile (21.3 to 20.9) 40 27 (67.5) [0.534–0.796] 4 (10.0) [0.035–0.214]
Fourth quartile (20.9 to 0.3) 40 21 (52.5) [0.385–0.662] 1 (2.5) [0.001–0.113]
Change in naive B cells/ml
First quartile (2725.0 to 2125.0) 19 10 (52.6) [0.320–0.726] 1 (5.3) [0.003–0.226]
Second quartile (2123.0 to 244.0) 20 14 (70.0) [0.492–0.860] 2 (10.0) [0.018–0.283]
Third quartile (241.0 to 212.0) 18 12 (66.7) [0.446–0.844] 2 (11.1) [0.020–0.310]
Fourth quartile (211.0 to 39.0) 21 15 (71.4) [0.513–0.868] 1 (4.8) [0.002–0.207]
Change in plasma cells/ml
First quartile (2107.0 to 213.0) 19 10 (52.6) [0.320–0.726] 2 (10.5) [0.019–0.296]
Second quartile (212.0 to 23.0) 16 13 (81.3) [0.583–0.947] 2 (12.5) [0.023–0.344]
Third quartile (22.0 to 21.0) 16 12 (75.0) [0.516–0.910] 1 (6.3) [0.003–0.264]
Fourth quartile (0.0 to 136.0) 27 16 (59.3) [0.417–0.752] 1 (3.7) [0.002–0.164]
Average serum concentration, ng/ml
First quartile (0.0 to 2,782.0) 41 27 (65.9) [0.519–0.780] 3 (7.3) [0.020–0.178]
Second quartile (2,823.7 to 3,892.0) 41 27 (65.9) [0.519–0.780] 7 (17.1) [0.083–0.297]
Third quartile (3,894.3 to 4,946.9) 41 23 (56.1) [0.421–0.694] 0 (0)
Fourth quartile (4,956.9 to 7,788.1) 41 20 (48.8) [0.351–0.626] 2 (4.9) [0.009–0.146]
* The potential completer population includes all patients who were randomized more than 52 weeks prior to termination
of the atacicept 150-mg arm. Values are the number (%) [90% confidence limit].
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lowest post-baseline values represented a 55.0% and a
77.0% decrease, respectively, from baseline (data not
shown).
Relationship between infection rate and atacicept
exposure. In the atacicept exposure analysis, there was
no difference in the overall infection rate between any
of the atacicept quartiles. Patients in the second quartile
appeared to have higher rates of serious or severe infec-
tion (17.1%; n5 7) compared with placebo (3.7%;
n5 3), but this result is difficult to interpret due to
small patient numbers. Patients with the highest
atacicept exposure levels had rates of serious or severe
infections similar to those in the placebo group (3.7%
in the placebo group and 4.9% in the atacicept fourth
quartile).
The 2 patients who died due to infection had
relatively low mean and maximum trough levels of
atacicept. Patient A, who died of pneumococcal pneu-
monia and alveolar hemorrhage, received atacicept
150 mg and had a mean atacicept concentration of
1,759 ng/ml in the fifth percentile and a maximum con-
centration of 3,511 ng/ml in the seventh percentile.
Patient B, who died of acute respiratory failure due to
alveolar hemorrhage secondary to possible leptospirosis,
had a mean concentration of 3,096 ng/ml in the 39th
percentile and a maximum concentration of 4,303 ng/ml
in the 29th percentile (results not shown).
DISCUSSION
It is well established that both BLyS and APRIL
have roles in the pathogenesis of B cell–mediated auto-
immunity, with elevated serum levels correlating with
disease severity in patients with SLE (15,19,20,23,24).
The results of this post hoc analysis of the APRIL-SLE
study are largely consistent with this evidence. In the
group treated with placebo, patients with the highest
baseline serum levels of both BLyS and APRIL (sub-
group 1) had the highest flare rates (75.7%), whereas
patients with the lowest levels of baseline BLyS (sub-
group 3) had the lowest flare rates (39.3%).
Another study showed that BLyS levels of $2.0
ng/ml at screening are an independent prognostic factor
for an increased risk of BILAG A or B flares (25).
Although the data reported here support this finding,
BLyS and APRIL levels in this trial were measured at
baseline after a 12-week steroid taper, as per the study
design. It is likely that steroid treatment led to some
decrease in the levels of BLyS and/or APRIL between
screening and the time of baseline measurement.
Indeed, improved disease activity was a prerequisite for
randomization into the study.
In the placebo group, the observed increase in
the flare rate between subgroup 2, in which only the
BLyS level was high, and subgroup 1, in which both the
BLyS and APRIL levels were high, suggests that APRIL
levels may also have a contributory role in flares, at least
in patients with high BlyS levels. In subgroup 3, which
consisted of patients with low BLyS levels at baseline,
APRIL levels had no effect on flare rates in the placebo
group. Although this suggests that APRIL alone may
not be prognostic for an increased risk of disease flare,
it is difficult to speculate what effect APRIL levels had
on flare in patients with low BLyS levels, due to the
small sample sizes in subgroup 3.
A treatment response with atacicept was
observed in the 2 patient subgroups with high baseline
BLyS levels. In subgroup 1, a clear dose-dependent
reduction in the flare rate was observed, and time to
new flare was delayed in those treated with atacicept.
The mechanism of action of atacicept should be consid-
ered when interpreting these results. A greater treat-
ment effect size might be expected in patients with
higher levels of the atacicept target molecules BLyS and
APRIL. Indeed, the observation that the treatment
response was more pronounced in subgroup 1, in which
levels of both BLyS and APRIL were high, compared
with subgroup 2, in which only BLyS levels were high,
supports the hypothesis that elevated levels of both
target molecules were required to achieve the maximum
treatment response. This observation also raised the
intriguing possibility that atacicept may be targeting
heterotrimeric forms of BLyS/APRIL. Although both
cytokines exist separately as homotrimers, heterotrimeric
complexes containing both BLyS and APRIL also exist
and are elevated in patients with autoimmune diseases
(19). It is plausible, therefore, that by targeting each of
these complexes, atacicept provides more complete inhi-
bition of BlyS- and APRIL-mediated B cell activation
and thus improved efficacy.
No response to treatment was observed in the
patient population with low BlyS levels; however,
because the flare rates were already low in this subgroup
(as seen in those patients receiving placebo), a pro-
nounced treatment effect was not expected. Interest-
ingly, the treatment response in patients with low BLyS
levels appeared not to be influenced by APRIL levels,
even though the difference in the flare rate between sub-
groups 1 and 2 suggests that APRIL levels are important.
Thus, BLyS levels above a minimum threshold level (e.g.,
$1.6 ng/ml in this trial)may be a prerequisite for a treatment
response, although the reasons for this remain unclear.
A correlation was observed between reduced
IgG levels and atacicept treatment. Notably, however,
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IgG levels in each study arm were comparable regard-
less of BLyS/APRIL levels, suggesting that the correla-
tion between BLyS/APRIL levels and treatment
response was not influenced by any variations in IgG
reductions.
We previously reported that levels of IgG, IgA,
and IgM as well as B cell and plasma cell numbers were
reduced in patients receiving atacicept compared with
those receiving placebo in the APRIL-SLE study (21).
Levels of anti-dsDNA antibodies were also reduced
with atacicept treatment compared with placebo treat-
ment in anti-dsDNA antibody–positive patients in the
potential completer population in the APRIL-SLE
study (21). This post hoc analysis suggests that greater
decreases in IgG, IgA, and IgM levels and naive B cell
and plasma cell numbers correlated with a greater treat-
ment response. Although the link between reduced Ig
levels and B cell counts and a reduced flare rate needs
to be further established, it is possible that this may be
attributable to a decreased production of pathogenic
autoantibodies and/or reduced pathogenic B cell activity
(e.g., cytokine production, antigen presentation to auto-
reactive T cells). Because only a subset of patients
(n5 119) consented to the flow cytometric analysis, the
observations on cell number reductions should be inter-
preted with caution.
There appeared to be an association between
increased levels of atacicept exposure and reduced flare
rates compared with placebo. Assuming that exposure
levels are linked to the atacicept dose, this finding may
account for the dose dependency seen in subgroups 1
and 2 in the BLyS/APRIL analysis. This would be con-
sistent with the initial results of the APRIL-SLE study,
which suggested that the higher atacicept dose, but not
the lower dose, was associated with significantly reduced
disease flare rates compared with placebo (21). The
patient who died of pneumococcal pneumonia and alve-
olar hemorrhage (patient A) had mean and maximum
concentrations of atacicept that fell within the fifth and
seventh percentiles for the 150-mg dose, respectively.
For context, the mean concentration of atacicept in the
75-mg group fell in the 10th percentile, and the maxi-
mum concentration was in the 25th percentile. Patient
A, therefore, had relatively low atacicept exposure,
despite receiving the higher dose. Taken together, these
findings imply that using the higher 150-mg dose of
atacicept may be more effective at controlling SLE dis-
ease activity than the lower 75-mg dose.
No statistically significant increased risk of infec-
tion with atacicept was observed in the APRIL-SLE
study; however, infections were the most commonly
reported serious adverse event (21). In this post hoc
analysis, no clinically meaningful differences in the rates
of overall or serious/severe infections were observed in
any of the patient groups. In the atacicept exposure
analysis, patients in the second quartile appeared to
have higher infection rates compared with placebo;
however, these values translated to a very small differ-
ence in actual patient numbers (n5 3 and n5 7 with
placebo and atacicept, respectively) and could be a
chance finding. Infection rates were not increased with
atacicept compared with placebo even in those patients
with the most pronounced reductions in IgG or IgA lev-
els or naive B cell or plasma cell numbers. Higher rates
of serious or severe infections were observed in patients
with the greatest IgM level reduction compared with
those with the least reduction, but these patient num-
bers were also too small to enable solid conclusions to
be drawn. As reported previously (21), both patients
who died due to fatal infections had IgG levels within
the normal range, IgM levels just below the normal
range, and atacicept concentrations within the lower
end of that in the 150-mg treatment group. These results
imply that neither the magnitude of pharmacodynamic
effects nor the exposure levels of atacicept are strongly
associated with infection rates. Infections are the most
common cause of death in lupus patients (26), and
patients should receive appropriate vaccinations regard-
less of whether they are receiving biologic agents (27).
In conclusion, this post hoc analysis shows that
the response to atacicept was greatest in patients with
high levels of both BLyS and APRIL, suggesting a
potential predictive role for these target molecules. A
potential stronger pharmacodynamic effect, as mea-
sured by Ig levels and B cell and plasma cell counts,
appeared to be associated with a greater treatment
response. It will be interesting to determine in future
studies whether there is a potential for these markers to
predict the likelihood of a clinical response. Impor-
tantly, increased atacicept exposure led to a more pro-
nounced reduction in the flare rate. In addition, we
could not detect an increased risk of infections associ-
ated with any subgroup, although the strength of this
observation is limited by the small number of patients
involved. These observations warrant the continued
exploration of the higher dose of atacicept in addition to
the lower dose in the ongoing phase IIb study, Efficacy
and Safety of Atacicept in Systemic Lupus Erythemato-
sus (ADDRESS II). These findings, however, provide
further support for the primary findings of the APRIL-
SLE study, indicating that atacicept has an acceptable
risk–benefit profile in patients with SLE and is worthy
of further study.
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